Invention Grant
- Patent Title: 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors
-
Application No.: US16309980Application Date: 2017-06-16
-
Publication No.: US10555935B2Publication Date: 2020-02-11
- Inventor: Xiaozhang Zheng , Pui Yee Ng , Mary-Margaret Zablocki
- Applicant: FORMA Therapeutics, Inc.
- Applicant Address: US MA Watertown
- Assignee: FORMA Therapeutics, Inc.
- Current Assignee: FORMA Therapeutics, Inc.
- Current Assignee Address: US MA Watertown
- Agency: Choate, Hall & Stewart LLP
- Agent Michael A. Shinall; Cristin E. Juda
- International Application: PCT/US2017/037970 WO 20170616
- International Announcement: WO2017/218950 WO 20171221
- Main IPC: A61K31/438
- IPC: A61K31/438 ; C07D401/04 ; C07D221/20 ; C07D401/06 ; C07D209/54 ; A61P25/14 ; A61P25/28 ; A61P35/00 ; A61K31/407
Abstract:
The present invention is directed to inhibitors of histone deacetylases (HDACs) such as HDAC6, and their use in the treatment of diseases such as cell proliferative diseases (e.g., cancer), neurological (e.g., neurodegenerative disease or neurodevelopmental disease), inflammatory or autoimmune disease, infection, metabolic disease, hematologic disease, or cardiovascular disease.
Public/Granted literature
- US20190201384A1 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS Public/Granted day:2019-07-04
Information query
